Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mini-dose Methotrexate Plus Steroids for Initial Treatment of Acute GVHD
NCT05921305Phase 3Recruiting
- Sponsor
- Peking University People's Hospital
- Start
- Aug 2023
- Primary completion
- Jun 2026
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of methotrexate in Acute Graft-Versus-Host Disease (aGvHD) (2 arms), sponsored by Peking University People's Hospital. Primary endpoint: Overall Response Rate at 14 days. Started Aug 2023; status: recruiting.
02
Drugs
methotrexate
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on NCT05921305.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05921305.